A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
This is a prospective, multicenter, open label study to investigate the safety and efficacy of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.
Metastatic Non-Small Cell Lung Cancer
DRUG: Gentuximab
Dose-limiting toxicities (DLT), Number of participants with one or more drug-related adverse events (AEs) defined as DLT in the protocol, Up to 4 Weeks|AEs or SAEs, Drug-related adverse events (AEs) or any serious adverse events (SAEs), Baseline through study completion, about 2 years
Cmax, Maximum Concentration, Cycle 1(day1-day 15)& Cycle 2(day 1-day15) & Cycle 3(day 1) & Cycle 4(day 1) (28 days for every cycle)|AUC, Area Under the Concentration-Time Curve, Cycle 1(day1-day 15)& Cycle 2(day 1-day15) & Cycle 3(day 1) & Cycle 4(day 1) (28 days for every cycle)|Objective response rate（ORR）, ORR is defined as the percentage of patients who have at least 1 response of CR or PR prior to any evidence of progression., From date of first dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Progression-free survival (PFS), PFS is defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression), From date of first dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Disease control rate (DCR), The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD, From date of first dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Anti-drug antibody number of participants With Anti-drug Antibodies, Number of participants with anti-drug antibodies, Cycle 1(day1-day 15)& Cycle 2(day 1) & Cycle 3(day 1) & Cycle 4(day 1) (28 days for every cycle)
This is a prospective, multicenter, open label study to investigate the safety and efficacy of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.